Small RNAs deliver a blow to ovarian cancer.
Small RNAs deliver a blow to ovarian cancer.
复制标题
DOI：
10.1158/2159-8290.cd-13-0667
复制
发表时间：
2013-11
期刊：
影响因子：
28.2
通讯作者：
Slack FJ
中科院分区：
文献类型：
--
作者：
Kasinski A;Slack FJ
过去十年，靶向治疗方法取得了巨大进步，这是有充分理由的。特别干预致病基因可以恢复有害表型，同时消除通常与广谱药物相关的毒性。不幸的是，由于这些选择性药剂击中单一位置的一个目标，因此获得性耐药性通常很高。可以说更好的治疗方法包括偶联多种靶向药物或使用一种药物在多个独立位置击中单个靶点和/或改变致病途径中的多个相关靶点，这正是 George Calin、Anil Snood 及其同事在他们最近的报告中采取的方法，旨在确定更好的卵巢癌治疗选择。
Targeted therapeutic approaches have seen tremendous advances in the last decade, for good reason. Specifically intervening with a disease-causing gene can revert the deleterious phenotype while eliminating the toxicity often associated with broad-spectrum agents. Unfortunately, because these selective agents hit one target in a single location, acquired resistance is often high. An arguably better treatment approach includes coupling multiple targeted agents or using an agent that hits an individual target in several independent locations and/or alters multiple relevant targets in the disease-causing pathway(s), precisely the approach taken by George Calin, Anil Snood, and colleagues in their recent report aimed at identifying a better treatment option for ovarian cancer.